{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:08:17Z","timestamp":1785546497153,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Evaluating the impact for different number of Anti-vascular endothelial growth Factor (VEGF) injections on macular neovascularization (MNV) secondary to pathological myopia, during a 2-year follow-up period, in relation to visual outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter, retrospective study of patients with myopic MNV (mMNV) for 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 55 patients with mMNV, with a mean age of 65.7\u2009\u00b1\u200914.5 years, met the inclusion criteria. The mean number of injections was significantly higher during the first year of follow-up with 8.78\u2009\u00b1\u20092.90 within the 1st year versus 3.45\u2009\u00b1\u20094.40 during the 2nd year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037). Visual acuity (VA) remained relatively stable throughout the follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.902), with most patients maintaining their vision or experiencing a loss of up to 5 Snellen letters. (42 patients, 76.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>During a 24-month period, there was a lack of BCVA improvement, which may be attributed to the PRN injection regimen and the relatively low number of injections administered for mMNV. These findings suggest that mMNV may be undertreated in routine practice, with suboptimal intravitreal injection frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>What is known<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The PRN injection regimen is widely used for treating myopic macular neovascularization (mMNV) due to its less aggressive nature and the potential risks of retinal break, retinal detachment, and other complications in highly myopic eyes.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>What is new<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>At the 24-month follow-up, patients with mMNV treated with anti-VEGF agents in a PRN regimen showed no significant improvement in BCVA.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Myopic MNV may be fallacy thought of as a less aggressive pathology and therefore is undertreated and perhaps may require a much more intensive injection schedule.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-06973-9","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:34:05Z","timestamp":1758882845000},"page":"3395-3402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myopic macular neovascularization treatment: A 2-year follow-up of a real-life cohort"],"prefix":"10.1007","volume":"263","author":[{"given":"Assaf","family":"Hilely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-8574","authenticated-orcid":false,"given":"Roee","family":"Arnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Lerann","family":"Shad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Trivizki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Rabina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"6973_CR1","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","volume":"89","author":"QD Nguyen","year":"2005","unstructured":"Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368. https:\/\/doi.org\/10.1136\/bjo.2005.066431","journal-title":"Br J Ophthalmol"},{"key":"6973_CR2","doi-asserted-by":"publisher","unstructured":"Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 12. https:\/\/doi.org\/10.1002\/14651858.CD011160.PUB2","DOI":"10.1002\/14651858.CD011160.PUB2"},{"key":"6973_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.006","author":"JM Ruiz-Moreno","year":"2013","unstructured":"Ruiz-Moreno JM, L\u00f3pez-G\u00e1lvez MI, Montero Moreno JA, Pastor Jimeno JC (2013) Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.006","journal-title":"Ophthalmology"},{"key":"6973_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004256","author":"S Swaminathan","year":"2024","unstructured":"Swaminathan S, Mahmoudzadeh R, Wakabayashi T, Bowers M, Momenaei B, Abishek RM (2024) Outcomes of pro re nata versus treat-and-extend anti-vascular endothelial growth factor injections for myopic macular neovascularization in multiethnic patients in the United States. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000004256","journal-title":"Retina"},{"key":"6973_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/JOP.2011.0106","volume":"28","author":"TT Wu","year":"2012","unstructured":"Wu TT, Kung YH (2012) The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther 28:129. https:\/\/doi.org\/10.1089\/JOP.2011.0106","journal-title":"J Ocul Pharmacol Ther"},{"key":"6973_CR6","doi-asserted-by":"publisher","unstructured":"Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F (2010) Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 128. https:\/\/doi.org\/10.1001\/archophthalmol.2009.408","DOI":"10.1001\/archophthalmol.2009.408"},{"key":"6973_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.130260","author":"L Arias","year":"2008","unstructured":"Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O et al (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjo.2007.130260","journal-title":"Br J Ophthalmol"},{"key":"6973_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.023","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T et al (2014) Radiance: a randomized controlled study of Ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.023","journal-title":"Ophthalmology"},{"key":"6973_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.06.010","author":"A Tufail","year":"2013","unstructured":"Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC et al (2013) Ranibizumab in myopic choroidal neovascularization: the 12-month results from the repair study. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2013.06.010","journal-title":"Ophthalmology"},{"key":"6973_CR10","doi-asserted-by":"publisher","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T et al (2015) Intravitreal Aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.025","DOI":"10.1016\/j.ophtha.2015.01.025"},{"key":"6973_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002292","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R et al (2019) Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000002292","journal-title":"Retina"},{"key":"6973_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700422","author":"S Mandal","year":"2007","unstructured":"Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/112067210701700422","journal-title":"Eur J Ophthalmol"},{"key":"6973_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6703052","author":"JM Ruiz-Moreno","year":"2009","unstructured":"Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M et al (2009) Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. https:\/\/doi.org\/10.1038\/sj.eye.6703052","journal-title":"Eye"},{"key":"6973_CR14","doi-asserted-by":"publisher","unstructured":"Chan WM, Lai TYY, Liu DTL, Lam DSC (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six-Month results of a prospective pilot study. Ophthalmology 114. https:\/\/doi.org\/10.1016\/j.ophtha.2007.03.043","DOI":"10.1016\/j.ophtha.2007.03.043"},{"key":"6973_CR15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1545817","author":"M Ladaique","year":"2015","unstructured":"Ladaique M, Dirani A, Ambresin A (2015) Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal Ranibizumab. Klin Monbl Augenheilkd. https:\/\/doi.org\/10.1055\/s-0035-1545817","journal-title":"Klin Monbl Augenheilkd"},{"key":"6973_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181c9691e","author":"RM Silva","year":"2010","unstructured":"Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro \u00c2, Nascimento J, Rito LF et al (2010) Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. https:\/\/doi.org\/10.1097\/IAE.0b013e3181c9691e","journal-title":"Retina"},{"key":"6973_CR17","unstructured":"Ravenstijn M, CCW Klave;Yzer S (2022) Myopic choroidal neovascularization: a long-term follow-up of anti-VEGF treatment in a large European cohort. Invest Ophthalmol Visual Scienc 63(7):3808\u2013F0229"},{"key":"6973_CR18","doi-asserted-by":"publisher","unstructured":"Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S et al (2003) Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 110. https:\/\/doi.org\/10.1016\/S0161-6420(03)00461-5","DOI":"10.1016\/S0161-6420(03)00461-5"},{"key":"6973_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/IAE.0B013E3181C9691E","volume":"30","author":"RM Silva","year":"2010","unstructured":"Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro \u00c2, Nascimento J, Rito LF et al (2010) Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30:407\u2013412. https:\/\/doi.org\/10.1097\/IAE.0B013E3181C9691E","journal-title":"Retina"},{"key":"6973_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-024-64456-Z","author":"Y Honda","year":"2024","unstructured":"Honda Y, Miyata M, Miyake M, Hata M, Numa S, Mori Y et al (2024) Differences between pathologic and non-pathologic high myopia in 4-year outcomes of anti-VEGF therapy for macular neovascularization. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-024-64456-Z","journal-title":"Sci Rep"},{"key":"6973_CR21","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/IAE.0000000000003869","volume":"43","author":"R Sakata","year":"2023","unstructured":"Sakata R, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Muraoka Y et al (2023) Ten-year visual outcome and change in chorioretinal atrophy after intravitreal ranibizumab for macular neovascularization in pathologic myopia. Retina 43:1863\u20131871. https:\/\/doi.org\/10.1097\/IAE.0000000000003869","journal-title":"Retina"},{"key":"6973_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2022-067921","author":"L Dong","year":"2023","unstructured":"Dong L, Li G, Song Z, Cheng X, Bai J, Zhang C (2023) Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. https:\/\/doi.org\/10.1136\/BMJOPEN-2022-067921","journal-title":"BMJ Open"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06973-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:39:49Z","timestamp":1770647989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06973-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6973"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06973-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB) of Meir Medical Center, Kfar Saba and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No Conflicts of Interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}